Knowing that Ga-68 PSMA PET/CT would not be cost-effective to be performed in all prostate cancer patients, it might be the modality of choice for patients with clinical or biochemical suspicion for metastatic disease, despite negative bone scan and conventional imaging results. The gene discussed is FOLH1; the disease is metastatic neoplasm.